Education
About Us
Working with TipRanks
Follow Us
Qiagen NV (QGEN)
NYSE:QGEN
Top Page
Qiagen
(NYSE:QGEN)
74Outperform
Positive Factors
Capital Allocation
The intent to return ~$300mn in shareholder capital is seen as a disciplined and shareholder-friendly capital allocation strategy by QIAGEN.
Earnings Guidance
Management increased its full-year CER earnings guidance and expects to reach its 31% operating margin target ahead of the original timeframe.
Financial Performance
Preliminary first-quarter results handedly beat both top- and bottom-line estimates.
Negative Factors
Instrument Demand
The one blemish was cautious instrument demand, which was not surprising.
Market Sentiment
Investor ambivalence remains a headwind for QGEN.
Sales Growth
Near-term sentiment for QDI is softer, with sales tracking below long-range plans due to overall biopharma weakness and the SaaS transition.
Qiagen (QGEN) vs. S&P 500 (SPY)
Market Cap
$9.09B
Dividend YieldN/A
Average Volume (3M)1.38M
Price to Earnings (P/E)113.2
Beta (1Y)0.72
Revenue Growth0.66%
EPS Growth-75.89%
CountryUS
Employees5,067
SectorHealthcare
Sector Strength69
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.37
Shares Outstanding216,116,100
10 Day Avg. Volume1,487,735
30 Day Avg. Volume1,382,310
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.34
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$48.49Price Target Upside15.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Qiagen Business Overview & Revenue Model
Company DescriptionQIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
How the Company Makes MoneyQiagen generates revenue through the sale of its diverse range of products and services designed to automate and streamline the process of extracting, analyzing, and interpreting molecular information. Its key revenue streams include: 1) Consumables and related products, comprising kits and reagents used in sample preparation and molecular testing. 2) Instruments, which include automation systems for sample processing and analysis. 3) Bioinformatics solutions, providing software and services for data interpretation and analysis. Additionally, Qiagen benefits from strategic partnerships and collaborations with academic institutions, pharmaceutical companies, and clinical laboratories, which enhance its market reach and drive sales growth. The company's focus on innovation and expanding its product offerings in high-demand areas, such as oncology and infectious disease testing, also significantly contributes to its earnings.
Qiagen Financial Statement Overview
Summary
Qiagen exhibits a solid financial foundation with strong cash flow and balance sheet metrics. Despite revenue and net profit margin declines, the company maintains efficiency and stable leverage, indicating a potential for improved profitability.Income Statement
Qiagen's revenue has shown fluctuations over the years, with a notable decline from 2021 to 2024. The gross profit margin remains relatively strong, indicating efficient cost management. However, the net profit margin has decreased significantly due to a fall in net income, suggesting challenges in maintaining profitability.72
Positive
Balance Sheet
The company's balance sheet is relatively strong, with a solid equity position. The debt-to-equity ratio has improved, indicating a stable leverage situation. However, the return on equity has decreased, reflecting reduced profitability relative to shareholder investments.75
Positive
Cash Flow
Qiagen has demonstrated strong cash flow management, with consistent free cash flow generation. The operating cash flow to net income ratio is healthy, suggesting effective conversion of income to cash. There is substantial growth in free cash flow, despite fluctuations in net income.80
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.98B | 1.97B | 2.14B | 2.25B | 1.87B | Gross Profit |
| 1.32B | 1.22B | 1.38B | 1.45B | 1.23B | EBIT |
| 97.71M | 445.25M | 531.46M | 630.08M | 554.90M | EBITDA |
| 702.07M | 688.55M | 779.36M | 895.24M | 715.80M | Net Income Common Stockholders |
| 83.59M | 341.30M | 423.21M | 512.60M | 73.64M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.15B | 1.06B | 1.42B | 1.07B | 714.25M | Total Assets |
| 5.69B | 6.12B | 6.29B | 6.15B | 5.97B | Total Debt |
| 1.39B | 1.61B | 1.86B | 1.94B | 2.03B | Net Debt |
| 727.99M | 943.04M | 1.13B | 1.06B | 1.43B | Total Liabilities |
| 2.12B | 2.31B | 2.82B | 3.05B | 3.49B | Stockholders Equity |
| 3.57B | 3.81B | 3.47B | 3.10B | 2.48B |
| Cash Flow | Free Cash Flow | |||
| 506.38M | 296.65M | 565.93M | 432.47M | 188.03M | Operating Cash Flow |
| 673.55M | 459.45M | 715.26M | 639.00M | 492.27M | Investing Cash Flow |
| -249.23M | -87.66M | -726.76M | -202.43M | -453.29M | Financing Cash Flow |
| -422.90M | -433.83M | -125.80M | -150.37M | -74.32M |
Qiagen Technical Analysis
Positive
42.07
Price Trends
39.94
Positive
42.20
Negative
43.09
Negative
Market Momentum
0.62
Negative
55.48
Neutral
66.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Positive. The current price of 42.07 is above the 20-day moving average (MA) of 40.85, above the 50-day MA of 39.94, and below the 200-day MA of 43.09, indicating a neutral trend. The MACD of 0.62 indicates Negative momentum. The RSI at 55.48 is Neutral, neither overbought nor oversold. The STOCH value of 66.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QGEN.
Qiagen Risk Analysis
Qiagen disclosed 38 risk factors in its most recent earnings report. Qiagen reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Qiagen Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $19.40B | 21.96 | 13.35% | 1.73% | 9.38% | 6.43% | |
74 Outperform | $9.09B | 113.24 | 2.27% | ― | 0.66% | -75.89% | |
68 Neutral | $20.79B | ― | -19.42% | ― | 56.75% | 59.77% | |
56 Neutral | $11.33B | 39.15 | 3.64% | 0.30% | 0.16% | -57.72% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
51 Neutral | $12.24B | ― | -30.11% | ― | -2.93% | -4.69% | |
50 Neutral | $8.44B | ― | -37.09% | ― | 10.37% | -389.98% |
* Healthcare Sector Average
Performance Comparison
QGEN
Qiagen
42.07
-0.22
-0.52%
EXAS
Exact Sciences
45.46
-13.32
-22.66%
ILMN
Illumina
77.35
-43.87
-36.19%
RVTY
Revvity
94.29
-10.46
-9.99%
DGX
Quest Diagnostics
173.76
37.03
27.08%
NTRA
Natera
153.79
59.75
63.54%
Qiagen Earnings Call Summary
Earnings Call Date: Feb 5, 2025 | % Change Since: -3.95% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
Qiagen N.V. delivered a strong performance in Q4 2024, exceeding expectations in net sales and adjusted earnings, with significant growth in key product segments and improved profitability. However, challenges remain in specific regions and market segments, with cautious market conditions and declines in certain areas such as the Asia Pacific Japan region and Sample Technologies. Overall, the achievements and growth initiatives position the company well for future growth, despite current challenges.Highlights
Strong Performance and Outlook Exceeded
Qiagen N.V. exceeded its Q4 2024 outlook for both net sales and adjusted earnings, with net sales at €521 million, growing 3% CER, and adjusted diluted EPS at $0.61 CER, surpassing the target of at least $0.60 CER.
Record Growth in Key Segments
KIAstat Diagnostics saw 25% CER growth in Q4 2024, with over 616 new system placements. QuantiFERON achieved 14% growth in Q4 and 11% CER growth for the year.
Significant Improvements in Profitability
Adjusted operating income margin rose by 2.6 percentage points in Q4 2024 to 30.6% of sales. Free cash flow increased by 63% to €506 million in 2024 compared to 2023.
Successful Product Launches and FDA Clearances
FDA clearances were achieved for four panels for the KIAstat Dx syndromic testing system, and QIAcuity diagnostic capabilities were expanded for clinical use.
Commitment to Shareholder Returns
Qiagen N.V. completed a $300 million share repurchase early 2025, reaffirming its commitment to return at least $1 billion to shareholders by the end of 2028.
Lowlights
Decline in Asia Pacific Japan Region
Sales in the Asia Pacific Japan region declined 5% CER in Q4 2024, with China sales declining at a low teens CER rate compared to the previous year.
Softness in Sample Technologies
Sample Technologies sales declined slightly in Q4 2024 due to weaker instrument sales, with a 3% CER decline for the full year, impacted by pandemic headwinds.
Cautious Market Conditions
The company noted cautious spending by customers and a challenging macro environment, which could impact growth and require a balanced view on market challenges.
Company Guidance
During the Qiagen N.V. Q4 2024 earnings call, the company reported strong financial performance, exceeding their outlook for both net sales and adjusted earnings. They achieved net sales of €521 million in Q4, marking a 3% growth at constant exchange rates (CER), and surpassed their goal of €520 million CER. The company's core business sales grew 4% CER, excluding discontinued products. Adjusted diluted EPS was $0.61 CER, exceeding the target of $0.60 CER. For the full year 2024, Qiagen exceeded their net sales outlook of €1.985 billion CER and adjusted EPS outlook of $2.19 CER. Key growth contributors included the KIAstat Diagnostics with 25% CER growth in Q4 and QuantiFERON with 14% growth in Q4. Qiagen also expanded their QIAcuity digital PCR platform and achieved a 63% increase in free cash flow to €506 million in 2024. The company announced a new synthetic share repurchase of approximately $300 million, reaffirming their commitment to returning at least $1 billion to shareholders by 2028. Looking forward, Qiagen expects net sales growth of approximately 4% CER and adjusted diluted EPS of at least $2.28 CER for 2025.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.